Welcome to our dedicated page for CG Oncology SEC filings (Ticker: CGON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CG Oncology, Inc. (NASDAQ: CGON) SEC filings page provides access to the company’s official U.S. Securities and Exchange Commission disclosures related to its late-stage clinical biopharmaceutical activities in non-muscle invasive bladder cancer (NMIBC). As a public company, CG Oncology files periodic and current reports that describe its financial condition, governance changes, and key clinical and regulatory milestones for its investigational intravesical oncolytic immunotherapy, cretostimogene grenadenorepvec.
Among the most relevant documents for CGON are current reports on Form 8-K, which the company uses to report material events. Recent 8-K filings have detailed board of director changes, including the appointment of a new director and the resignation of another, as well as transitions in the principal financial and accounting officer role. Other 8-Ks reference press releases announcing quarterly financial results, updated BOND-003 Cohort C data in high-risk BCG-unresponsive NMIBC, and corporate presentations at healthcare conferences.
Investors also look to CG Oncology’s quarterly and annual reports (Forms 10-Q and 10-K, when available) for broader context on its clinical development program, including the BOND-003 and PIVOT-006 Phase 3 trials and the CORE-008 Phase 2 study, as well as information about its Expanded Access Program in North America. These filings typically discuss risk factors, research and development expenses, and other elements that shape the company’s outlook as a late-stage clinical biopharmaceutical issuer.
On Stock Titan, CGON filings are updated as they are posted to EDGAR, and AI-powered tools can help summarize lengthy documents such as earnings-related 8-K exhibits or future 10-K and 10-Q reports. Users can also review governance and compensation disclosures embedded in 8-K items related to director appointments and executive transitions, and track how these developments align with CG Oncology’s efforts to advance cretostimogene through the regulatory process.
Insider transactions by CG Oncology (CGON) director James J. Mulay on 09/29/2025: Mr. Mulay exercised 12,755 fully vested director stock options at an exercise price of $1.82 per share, converting them into 12,755 shares of common stock. On the same date those 12,755 shares were sold under a Rule 10b5-1 trading plan at a weighted average price of $39.19 per share (individual sale prices ranged from $38.99 to $39.41). Following the reported transactions, the reporting person holds no common shares but retains the director stock option record showing 12,755 underlying shares with an exercise price of $1.82 and an expiration of 07/18/2031. The Form 4 was signed by an attorney-in-fact.
CG Oncology, Inc. filing a Form 144 notifies the proposed sale of 5,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $195,400, to be sold on 09/30/2025 on NASDAQ. The shares were acquired the same day by exercise of stock options and paid in cash. The filer reports prior Rule 10b5-1 sales by Leonard E. Post totaling 4,000 shares in the past three months (2,000 sold on 07/17/2025 for $56,000; 1,000 on 09/03/2025 for $28,000; 1,000 on 09/15/2025 for $35,100). The filing shows 76,247,581 shares outstanding, so the proposed sale represents a de minimis fraction of outstanding shares.
James J. Mulay, a director of CG Oncology, Inc. (CGON), reported option exercises and immediate sales on September 18-19, 2025. On 09/18/2025 he exercised Director Stock Options to acquire 19,112 shares at an exercise price of $1.82 per share and, pursuant to a Rule 10b5-1 trading plan adopted June 6, 2025, sold those 19,112 shares at a weighted average price of $39.01. On 09/19/2025 he exercised an additional 3,574 options at $1.82 and sold those 3,574 shares at $38.99. The filing states the options were fully vested and the sales reduced the reported non-derivative beneficial ownership to zero following the transactions. The form is signed by an attorney-in-fact on behalf of Mr. Mulay.
Longitude-affiliated investors disclosed ownership in CG Oncology (CGON), holding a combined economic interest of 4,662,268 shares, representing 6.0% of the outstanding common stock based on 77,762,732 shares. Record owners include Longitude Venture Partners IV, L.P. (3,190,463 shares, 4.1%) and Longitude Prime Fund, L.P. (1,471,805 shares, 1.9%). The filing describes prior private purchases of preferred and common stock between 2022 and 2023 that converted into common stock upon the issuer’s IPO. The Reporting Persons say holdings are for general investment purposes, reserve the right to change their position, and note that a Longitude managing director serves on CG Oncology’s board. The filing references investor registration rights and disclaims current plans for any specific corporate actions.
Seven Fleet filed a Schedule 13D disclosing an open-market purchase of CG Oncology common stock. Seven Fleet Partners purchased 1,540,819 shares for approximately $49,999,983, including a tranche of 1,515,151 shares bought on September 11, 2025 at $33.00 per share under the issuer's at-the-market offering. The filing reports beneficial ownership of 1,515,151 shares (1.9%) by the reporting entities based on 77,762,732 shares outstanding; Dr. Brian Liu is shown with shared voting power and direct holdings equating to 2%. The Reporting Persons state they view the shares as undervalued and may buy or sell, engage with management, or consider other strategic actions.
CG Oncology, Inc. (CGON) filed a Form 144 reporting a proposed sale of 35,441 common shares with an aggregate market value of $1,336,834.52. The notice lists Morgan Stanley Smith Barney LLC as the broker and identifies the approximate sale date as 09/18/2025 on NASDAQ. The shares were recorded as acquired on 09/18/2025 through an exercise of stock options, paid in cash. The filing also discloses a prior Rule 10b5-1 sale by James J. Mulay of 27,015 shares on 09/05/2025 for gross proceeds of $851,759.01. The filer represents no undisclosed material adverse information.
Leonard E. Post, a director of CG Oncology, Inc. (CGON), reported transactions dated 09/15/2025. He exercised a director stock option with a $0.60 exercise price to acquire 1,000 shares (option fully vested). On the same date he sold 1,000 shares at $35.10 per share; the filing states the sale was effected under a Rule 10b5-1 trading plan adopted by the reporting person on 09/06/2024. Following these transactions, the filing reports total beneficial ownership of 124,077 shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Post on 09/16/2025.
Brian Guan-Chyun Liu, a director of CG Oncology, Inc. (CGON), reported a purchase of 1,515,151 shares of the company's common stock on 09/11/2025 at a price of $33 per share. The filing shows the shares were acquired (transaction code P) and that 1,515,151 shares were beneficially owned following the transaction. Ownership is reported as indirect through Seven Fleet Partners LP; Liu disclaims direct beneficial ownership except to the extent of any pecuniary interest. The form is signed on 09/12/2025.
CG Oncology, Inc. filed a current report to let investors know it plans to discuss an updated corporate presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference on September 9, 2025. The presentation, dated the same day, is provided as Exhibit 99.1 and is incorporated by reference in the report.
The company emphasizes that the information in the presentation is being furnished under Regulation FD and is not considered "filed" for purposes of certain liability provisions under U.S. securities laws, unless specifically incorporated into other documents. CG Oncology also notes it has no obligation to update the presentation, though future updates may be made through additional SEC filings or other public disclosures.
James J. Mulay, a director of CG Oncology, Inc. (CGON), exercised a fully vested director stock option to buy 27,015 shares at an exercise price of $0.60 on 09/05/2025. The same day he sold a total of 27,015 common shares under a Rule 10b5-1 trading plan adopted June 6, 2025, at weighted-average prices ranging across four blocks: $30.47, $31.42, $32.64, and $33.22. Following these transactions the reporting person reports 0 shares beneficially owned. Sales were effected pursuant to the 10b5-1 plan and the option was fully vested.